Vmn2r62 Inhibitors
Vmn2r62 can act through various mechanisms to inhibit the protein's function. Benzamidine and Phenylmethylsulfonyl fluoride (PMSF) are examples of inhibitors that target serine protease-like domains. Benzamidine acts as a competitive inhibitor, likely interacting with the active site of the protease domain essential for Vmn2r62's ligand processing. PMSF, on the other hand, irreversibly binds to serine residues at the active site, thus preventing the enzymatic activity necessary for Vmn2r62's function. Similarly, Leupeptin and Aprotinin inhibit serine proteases, with leupeptin having the added ability to inhibit cysteine proteases, suggesting it could affect Vmn2r62 if its activity is mediated by such protease activities. Aprotinin functions through a mechanism of protease inhibition by binding to various serine proteases, which could be modulating Vmn2r62's activity.
E-64 and N-ethylmaleimide (NEM) target cysteine residues that could be crucial for Vmn2r62's structure or interaction with other proteins. E-64 can covalently bind to the active site thiol group of cysteine proteases, potentially inhibiting any cysteine protease-like domain within Vmn2r62. NEM, on the contrary, alkylates free sulfhydryl groups which could be essential for Vmn2r62's function or its regulatory interactions. Chymostatin, which is specific for chymotrypsin-like serine proteases, could inhibit Vmn2r62 if it relies on such protease activity for its function. Marimastat, a broad-spectrum inhibitor of matrix metalloproteases, could impede any MMP-dependent proteolytic processing that Vmn2r62 might require. Lastly, inhibitors like Allopurinol, PD 98059, and LY294002 target other enzymatic pathways. Allopurinol inhibits xanthine oxidase, which could be involved in the regulation of Vmn2r62, while PD 98059 and LY294002 inhibit the MAPK/ERK kinase and phosphoinositide 3-kinases (PI3K) pathways, respectively. These latter inhibitors could decrease Vmn2r62 signaling if it is connected to these pathways, by preventing upstream kinase activity or the generation of secondary messengers.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Benzamidine | 618-39-3 | sc-233933 | 10 g | $292.00 | 1 | |
Benzamidine is a known serine protease inhibitor that can inhibit Vmn2r62 by targeting the protease domain, which is essential for the receptor's ligand processing and activation. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is a potent inhibitor of cysteine proteases. If Vmn2r62 has a cysteine protease-like domain or is regulated by cysteine proteases, E-64 can inhibit its function by covalently binding to the active site thiol group. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
NEM alkylates free sulfhydryl groups on cysteine residues. If Vmn2r62's activity is dependent on cysteine residues in a functional domain or if it interacts with proteins that have critical cysteines, NEM can disrupt its function. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a reversible inhibitor of serine and cysteine proteases. If Vmn2r62 has a serine or cysteine protease-like activity or is modulated by such proteases, leupeptin can inhibit these enzymatic functions and, therefore, inhibit Vmn2r62. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Aprotinin is a small protein protease inhibitor that inhibits several serine proteases. If Vmn2r62 is modulated via serine protease activity, Aprotinin can bind to these proteases and inhibit their activity, thereby inhibiting Vmn2r62. | ||||||
Chymostatin | 9076-44-2 | sc-202541 sc-202541A sc-202541B sc-202541C sc-202541D | 5 mg 10 mg 25 mg 50 mg 100 mg | $156.00 $260.00 $640.00 $1186.00 $2270.00 | 3 | |
Chymostatin is a specific inhibitor of chymotrypsin-like serine proteases. If Vmn2r62's function is mediated through chymotrypsin-like protease activity, chymostatin can inhibit this protease and consequently the function of Vmn2r62. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor. If Vmn2r62 is involved in a pathway with MMPs, Marimastat can inhibit these proteases and therefore potentially inhibit the proteolytic processing required for Vmn2r62 function. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol is a xanthine oxidase inhibitor. If Vmn2r62's function is linked to reactive oxygen species production via xanthine oxidase, Allopurinol can inhibit this enzyme and therefore the signaling pathway involving Vmn2r62. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of mitogen-activated protein kinase (MAPK/ERK) kinase. If Vmn2r62 signaling relies on the MAPK/ERK pathway, PD 98059 can inhibit this pathway upstream, thereby inhibiting Vmn2r62 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. If Vmn2r62 operates within a PI3K-dependent signaling pathway, inhibition of PI3K by LY294002 would lead to a decrease in downstream signaling and inhibit Vmn2r62 function. | ||||||